International Journal of Hematology

, Volume 108, Issue 3, pp 298–305 | Cite as

Extracorporeal photopheresis with TC-V in Japanese patients with steroid-resistant chronic graft-versus-host disease

  • Shinichiro OkamotoEmail author
  • Takanori Teshima
  • Mizuha Kosugi-Kanaya
  • Kaoru Kahata
  • Naomi Kawashima
  • Jun Kato
  • Takehiko Mori
  • Yukiyasu Ozawa
  • Koichi Miyamura
Original Article


There are few established therapies for chronic graft-versus-host disease (cGVHD) refractory to first-line treatment with steroids. We evaluated the efficacy and safety of extracorporeal photopheresis (ECP) with a third-generation TC-V device in Japanese patients with cGVHD. Fifteen patients with steroid-resistant or -intolerant cGVHD after allogeneic hematopoietic stem cell transplantation participated in this multicenter open-label study. Extracorporeal photopheresis was conducted on days 1–3, week 1; days 1–2, weeks 2–12; and days 1–2, weeks 16, 20, and 24. The composite primary endpoint consisted of evaluation of response and changes in steroid dose 24 weeks after ECP initiation. Secondary endpoints included response over time, concomitant drug dose, quality of life, and safety. Twelve patients completed scheduled ECP therapy; eight (66.7%) showed a response at week 24. In all 15 patients, the mean (± standard deviation) steroid dose decreased 0.115 ± 0.230 mg/kg/day from screening to week 24. Five serious, potentially treatment-related adverse events (heart failure, thrombosis in the device, pneumonia, edema, and wheezing) occurred; none were fatal. This study confirmed that ECP using the TC-V device was effective, with an acceptable toxicity profile. Further studies in larger cohorts are clearly warranted to determine its optimal use in Japanese patients with cGVHD.


Chronic graft-versus-host disease Extracorporeal photopheresis (ECP) Hematopoietic stem cell transplantation Steroid resistant 



The authors thank the doctors, nurses, and medical engineers at each site for their dedicated care and support of the patients.


This study was sponsored by Therakos Inc., a Mallinckrodt Pharmaceuticals company. Vorpal Technologies KK, an independent contract research organization, was solely responsible for the administration of the clinical trial and the verification of the data points. A representative of Mallinckrodt Pharmaceuticals was a member of the steering committee but did not participate in the design of the study. Thomas Chin, of Mallinckrodt Pharmaceuticals, was responsible for the statistical analysis; however, he neither participated in the verification of the data from the investigational sites (performed by Vorpal Technologies KK) nor in the data interpretation or the writing of this manuscript. We thank Vorpal Technologies KK for their role in the conduct of the study. We also thank Gail Flores, PhD, and Brian Bass, both of Bass Global, Inc., for medical writing and editorial assistance with this manuscript, which was financed by Mallinckrodt Pharmaceuticals. Finally, we thank all of the patients who participated in this study.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21:389–401.e1.CrossRefPubMedGoogle Scholar
  2. 2.
    Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011;29:2230–9.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Yu J, Storer BE, Kushekhar K, Abu Zaid M, Zhang Q, Gafken PR, et al. Biomarker panel for chronic graft-versus-host disease. J Clin Oncol. 2016;34:2583–90.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Garnett C, Apperley JF, Pavlu J. Treatment and management of graft-versus-host disease: improving response and survival. Ther Adv Hematol. 2013;4:366–78.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Stewart BL, Storer B, Storek J, Deeg HJ, Storb R, Hansen JA, et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood. 2004;104:3501–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Edelson R, Berger C, Gasparro F, Jegasothy B, Heald P, Wintroub B, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med. 1987;316:297–303.CrossRefPubMedGoogle Scholar
  7. 7.
    Hautmann AH, Wolff D, Hahn J, Edinger M, Schirmer N, Ammer J, et al. Extracorporeal photopheresis in 62 patients with acute and chronic GVHD: results of treatment with the COBE Spectra System. Bone Marrow Transplant. 2013;48:439–45.CrossRefPubMedGoogle Scholar
  8. 8.
    Berger M, Albiani R, Sini B, Fagioli F. Extracorporeal photopheresis for graft-versus-host disease: the role of patient, transplant, and classification criteria and hematologic values on outcome-results from a large single-center study. Transfusion. 2015;55:736–47.CrossRefPubMedGoogle Scholar
  9. 9.
    Dignan FL, Aguilar S, Scarisbrick JJ, Shaw BE, Potter MN, Cavenagh J, et al. Impact of extracorporeal photopheresis on skin scores and quality of life in patients with steroid-refractory chronic GVHD. Bone Marrow Transplant. 2014;49:704–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Malagola M, Cancelli V, Skert C, Leali PF, Ferrari E, Tiburzi A, et al. Extracorporeal photopheresis for treatment of acute and chronic graft versus host disease: an Italian multicentric retrospective analysis on 94 patients on behalf of the Gruppo Italiano Trapianto di Midollo Osseo. Transplantation. 2016;100:e147-e55.CrossRefGoogle Scholar
  11. 11.
    Abu-Dalle I, Reljic T, Nishihori T, Antar A, Bazarbachi A, Djulbegovic B, et al. Extracorporeal photopheresis in steroid-refractory acute or chronic graft-versus-host disease: results of a systematic review of prospective studies. Biol Blood Marrow Transplant. 2014;20:1677–86.CrossRefPubMedGoogle Scholar
  12. 12.
    Greinix HT, van Besien K, Elmaagacli AH, Hillen U, Grigg A, Knobler R, et al. Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis—results of a crossover randomized study. Biol Blood Marrow Transplant. 2011;17:1775–82.CrossRefPubMedGoogle Scholar
  13. 13.
    Apisarnthanarax N, Donato M, Korbling M, Couriel D, Gajewski J, Giralt S, et al. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplant. 2003;31:459–65.CrossRefPubMedGoogle Scholar
  14. 14.
    Bisaccia E, Palangio M, Gonzalez J, Adler KR, Scarborough R, Goldberg SL, et al. Treatment of extensive chronic graft-versus-host disease with extracorporeal photochemotherapy. J Clin Apher. 2006;21:181–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Child FJ, Ratnavel R, Watkins P, Samson D, Apperley J, Ball J, et al. Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versus-host disease (GVHD). Bone Marrow Transplant. 1999;23:881–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Couriel DR, Hosing C, Saliba R, Shpall EJ, Anderlini P, Rhodes B, et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood. 2006;107:3074–80.CrossRefPubMedGoogle Scholar
  17. 17.
    Del Fante C, Scudeller L, Viarengo G, Bernasconi P, Perotti C. Response and survival of patients with chronic graft-versus-host disease treated by extracorporeal photochemotherapy: a retrospective study according to classical and National Institutes of Health classifications. Transfusion. 2012;52:2007–15.CrossRefPubMedGoogle Scholar
  18. 18.
    Dignan FL, Greenblatt D, Cox M, Cavenagh J, Oakervee H, Apperley JF, et al. Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD. Bone Marrow Transplant. 2012;47:824–30.CrossRefPubMedGoogle Scholar
  19. 19.
    Flowers ME, Apperley JF, van Besien K, Elmaagacli A, Grigg A, Reddy V, et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood. 2008;112:2667–74.CrossRefPubMedGoogle Scholar
  20. 20.
    Foss FM, DiVenuti GM, Chin K, Sprague K, Grodman H, Klein A, et al. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplant. 2005;35:1187–93.CrossRefPubMedGoogle Scholar
  21. 21.
    Garban F, Drillat P, Makowski C, Jacob MC, Richard MJ, Favrot M, et al. Extracorporeal chemophototherapy for the treatment of graft-versus-host disease: hematologic consequences of short-term, intensive courses. Haematologica. 2005;90:1096–101.PubMedGoogle Scholar
  22. 22.
    Greinix HT, Volc-Platzer B, Rabitsch W, Gmeinhart B, Guevara-Pineda C, Kalhs P, et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood. 1998;92:3098–104.PubMedGoogle Scholar
  23. 23.
    Malik MI, Litzow M, Hogan W, Patnaik M, Murad MH, Prokop LJ, et al. Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis. Blood Res. 2014;49:100–6.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Perfetti P, Carlier P, Strada P, Gualandi F, Occhini D, Van Lint MT, et al. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. Bone Marrow Transplant. 2008;42:609–17.CrossRefPubMedGoogle Scholar
  25. 25.
    Rubegni P, Cuccia A, Sbano P, Cevenini G, Carcagni MR, D’Ascenzo G, et al. Role of extracorporeal photochemotherapy in patients with refractory chronic graft-versus-host disease. Br J Haematol. 2005;130:271–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Smith EP, Sniecinski I, Dagis AC, Parker PM, Snyder DS, Stein AS, et al. Extracorporeal photochemotherapy for treatment of drug-resistant graft-vs.-host disease. Biol Blood Marrow Transplant. 1998;4:27–37.CrossRefPubMedGoogle Scholar
  27. 27.
    Ussowicz M, Musial J, Mielcarek M, Tomaszewska A, Nasilowska-Adamska B, Kalwak K, et al. Steroid-sparing effect of extracorporeal photopheresis in the therapy of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplant Proc. 2013;45:3375–80.CrossRefPubMedGoogle Scholar
  28. 28.
    Inamoto Y, Kimura F, Kanda J, Sugita J, Ikegame K, Nakasone H, et al. Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups. Haematologica. 2016;101:1592–602.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Kanda J, Nakasone H, Atsuta Y, Toubai T, Yokoyama H, Fukuda T, et al. Risk factors and organ involvement of chronic GVHD in Japan. Bone Marrow Transplant. 2014;49:228–35.CrossRefPubMedGoogle Scholar
  30. 30.
    Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–56.CrossRefPubMedGoogle Scholar
  31. 31.
    Inamoto Y, Martin PJ, Chai X, et al. The clinical benefit of response in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2012;18(10):1517–1524.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    MacDonald KPA, Hill GR, Blazar BR. Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood. 2017;129(1):13–21.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2018

Authors and Affiliations

  • Shinichiro Okamoto
    • 1
    Email author
  • Takanori Teshima
    • 2
  • Mizuha Kosugi-Kanaya
    • 2
  • Kaoru Kahata
    • 3
  • Naomi Kawashima
    • 4
  • Jun Kato
    • 1
  • Takehiko Mori
    • 1
  • Yukiyasu Ozawa
    • 4
  • Koichi Miyamura
    • 4
  1. 1.Division of Hematology, Department of MedicineKeio University School of MedicineTokyoJapan
  2. 2.HematologyHokkaido University Faculty of Medicine and Graduate School of MedicineSapporoJapan
  3. 3.Laboratory and Transfusion MedicineHokkaido University HospitalSapporoJapan
  4. 4.HematologyJapanese Red Cross Nagoya First HospitalNagoyaJapan

Personalised recommendations